HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Amylyx Pharma (NASDAQ:AMLX) and maintained an $8 price target.

April 11, 2024 | 10:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amylyx Pharma maintains a Buy rating and an $8 price target from HC Wainwright & Co., indicating a positive outlook from the analyst.
The reiteration of a Buy rating and maintenance of an $8 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong belief in Amylyx Pharma's potential for growth. This positive analyst outlook can influence investor sentiment and potentially lead to a short-term increase in stock price, assuming market conditions do not change significantly.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100